Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors
The deal includes upfront payments, milestone payments and ongoing royalties
Comprehensive clinical development programs being initiated for each investigational candidate
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
AMI to become part of Enpro’s Sealing Technologies Segment
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Sirius JV will be owned 51% by Sirius and 49% by Adani
Marks remarkable acceleration in innovation using AI technology
The establishment of the facility demonstrates the company's commitment to delivering differentiated solutions to gynecology and pediatrics challenges
Subscribe To Our Newsletter & Stay Updated
